Selected research
Industry Research
Multiple Myeloma Drugs Industry Research Report 2026
Market perspective
The global Multiple Myeloma Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Multiple Myeloma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Multiple Myeloma Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Multiple Myeloma Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Multiple Myeloma Drugs include Takeda Pharmaceutical, Teva, Johnson & Johnson, Novartis, Merck, Amgen, PharmaMar, Daiichi Sankyo and Celgene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Multiple Myeloma Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Multiple Myeloma Drugs Market by Company
Takeda Pharmaceutical
Teva
Johnson & Johnson
Novartis
Merck
Amgen
PharmaMar
Daiichi Sankyo
Celgene
AB Science
Multiple Myeloma Drugs Segment by Type
Monoclonal Antibodies
Proteasome Inhibitors
Chemotherapy
Immunomodulators
Corticosteroids
Histone Deacetylase (HDAC) Inhibitors
Others
Multiple Myeloma Drugs Segment by Application
Men
Women
Multiple Myeloma Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Myeloma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Multiple Myeloma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Myeloma Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Multiple Myeloma Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Multiple Myeloma Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Multiple Myeloma Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monoclonal Antibodies
- Proteasome Inhibitors
- Chemotherapy
- Immunomodulators
- Corticosteroids
- Histone Deacetylase (HDAC) Inhibitors
- Others
Applications
- Men
- Women
Companies covered
- Takeda Pharmaceutical
- Teva
- Johnson & Johnson
- Novartis
- Merck
- Amgen
- PharmaMar
- Daiichi Sankyo
- Celgene
- AB Science
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Multiple Myeloma Drugs Market Size (2021-2032)
- 2.2.2 Global Multiple Myeloma Drugs Sales (2021-2032)
- 2.2.3 Global Multiple Myeloma Drugs Market Average Price (2021-2032)
- 2.3 Multiple Myeloma Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Monoclonal Antibodies
- 2.3.3 Proteasome Inhibitors
- 2.3.4 Chemotherapy
- 2.3.5 Immunomodulators
- 2.3.6 Corticosteroids
- 2.3.7 Histone Deacetylase (HDAC) Inhibitors
- 2.3.8 Others
- 2.4 Multiple Myeloma Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Men
- 2.4.3 Women
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Multiple Myeloma Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Multiple Myeloma Drugs Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Multiple Myeloma Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Multiple Myeloma Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Multiple Myeloma Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Multiple Myeloma Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Multiple Myeloma Drugs, Product Type & Application
- 3.8 Global Manufacturers of Multiple Myeloma Drugs, Established Date
- 3.9 Global Multiple Myeloma Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda Pharmaceutical
- 4.1.1 Takeda Pharmaceutical Company Information
- 4.1.2 Takeda Pharmaceutical Business Overview
- 4.1.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolio
- 4.1.5 Takeda Pharmaceutical Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Multiple Myeloma Drugs Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 Johnson & Johnson
- 4.3.1 Johnson & Johnson Company Information
- 4.3.2 Johnson & Johnson Business Overview
- 4.3.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Johnson & Johnson Multiple Myeloma Drugs Product Portfolio
- 4.3.5 Johnson & Johnson Recent Developments
- 4.4 Novartis
- 4.4.1 Novartis Company Information
- 4.4.2 Novartis Business Overview
- 4.4.3 Novartis Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis Multiple Myeloma Drugs Product Portfolio
- 4.4.5 Novartis Recent Developments
- 4.5 Merck
- 4.5.1 Merck Company Information
- 4.5.2 Merck Business Overview
- 4.5.3 Merck Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Multiple Myeloma Drugs Product Portfolio
- 4.5.5 Merck Recent Developments
- 4.6 Amgen
- 4.6.1 Amgen Company Information
- 4.6.2 Amgen Business Overview
- 4.6.3 Amgen Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Amgen Multiple Myeloma Drugs Product Portfolio
- 4.6.5 Amgen Recent Developments
- 4.7 PharmaMar
- 4.7.1 PharmaMar Company Information
- 4.7.2 PharmaMar Business Overview
- 4.7.3 PharmaMar Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 PharmaMar Multiple Myeloma Drugs Product Portfolio
- 4.7.5 PharmaMar Recent Developments
- 4.8 Daiichi Sankyo
- 4.8.1 Daiichi Sankyo Company Information
- 4.8.2 Daiichi Sankyo Business Overview
- 4.8.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Daiichi Sankyo Multiple Myeloma Drugs Product Portfolio
- 4.8.5 Daiichi Sankyo Recent Developments
- 4.9 Celgene
- 4.9.1 Celgene Company Information
- 4.9.2 Celgene Business Overview
- 4.9.3 Celgene Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Celgene Multiple Myeloma Drugs Product Portfolio
- 4.9.5 Celgene Recent Developments
- 4.10 AB Science
- 4.10.1 AB Science Company Information
- 4.10.2 AB Science Business Overview
- 4.10.3 AB Science Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AB Science Multiple Myeloma Drugs Product Portfolio
- 4.10.5 AB Science Recent Developments
5 Global Multiple Myeloma Drugs Market Scenario by Region
- 5.1 Global Multiple Myeloma Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Multiple Myeloma Drugs Sales by Region: 2021-2032
- 5.2.1 Global Multiple Myeloma Drugs Sales by Region: 2021-2026
- 5.2.2 Global Multiple Myeloma Drugs Sales by Region: 2027-2032
- 5.3 Global Multiple Myeloma Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Multiple Myeloma Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Multiple Myeloma Drugs Revenue by Region: 2027-2032
- 5.4 North America Multiple Myeloma Drugs Market Facts & Figures by Country
- 5.4.1 North America Multiple Myeloma Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Multiple Myeloma Drugs Sales by Country (2021-2032)
- 5.4.3 North America Multiple Myeloma Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Multiple Myeloma Drugs Market Facts & Figures by Country
- 5.5.1 Europe Multiple Myeloma Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Multiple Myeloma Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Multiple Myeloma Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Multiple Myeloma Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Multiple Myeloma Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Multiple Myeloma Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Multiple Myeloma Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Multiple Myeloma Drugs Market Facts & Figures by Country
- 5.7.1 South America Multiple Myeloma Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Multiple Myeloma Drugs Sales by Country (2021-2032)
- 5.7.3 South America Multiple Myeloma Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Multiple Myeloma Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Multiple Myeloma Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Multiple Myeloma Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Multiple Myeloma Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Multiple Myeloma Drugs Sales by Type (2021-2032)
- 6.1.1 Global Multiple Myeloma Drugs Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Multiple Myeloma Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Multiple Myeloma Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Multiple Myeloma Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Multiple Myeloma Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Multiple Myeloma Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Multiple Myeloma Drugs Sales by Application (2021-2032)
- 7.1.1 Global Multiple Myeloma Drugs Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Multiple Myeloma Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Multiple Myeloma Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Multiple Myeloma Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Multiple Myeloma Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Multiple Myeloma Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Multiple Myeloma Drugs Value Chain Analysis
- 8.1.1 Multiple Myeloma Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Multiple Myeloma Drugs Production Mode & Process
- 8.2 Multiple Myeloma Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Multiple Myeloma Drugs Distributors
- 8.2.3 Multiple Myeloma Drugs Customers
9 Global Multiple Myeloma Drugs Analyzing Market Dynamics
- 9.1 Multiple Myeloma Drugs Industry Trends
- 9.2 Multiple Myeloma Drugs Industry Drivers
- 9.3 Multiple Myeloma Drugs Industry Opportunities and Challenges
- 9.4 Multiple Myeloma Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst